161 related articles for article (PubMed ID: 36304630)
1. Caplacizumab in the successful management of cardiac involvement in thrombotic thrombocytopenic purpura.
Mahmoud AA; Eltaher B; Hashem A
Proc (Bayl Univ Med Cent); 2022; 35(6):832-833. PubMed ID: 36304630
[TBL] [Abstract][Full Text] [Related]
2. Refractory Auto-Immune Thrombotic Thrombocytopenic Pupura Successfully Treated With Caplacizumab.
Mellaza C; Henry N; Fayolle PM; Mortaza S; Subra JF; Veyradier A; Coppo P; Augusto JF
Front Med (Lausanne); 2020; 7():549931. PubMed ID: 33195299
[TBL] [Abstract][Full Text] [Related]
3. Management of immune thrombotic thrombocytopenic purpura with caplacizumab: a Canadian, single-centre, real-world experience.
Tse B; Buchholz M; Pavenski K
Platelets; 2023 Dec; 34(1):2157807. PubMed ID: 36636834
[TBL] [Abstract][Full Text] [Related]
4. Caplacizumab for relapsing thrombotic thrombocytopenic purpura.
Kaczmarek V; Holle J; Astudillo R; Kempf C; Bufler P; Müller D
Pediatr Nephrol; 2019 Sep; 34(9):1625-1628. PubMed ID: 31177334
[TBL] [Abstract][Full Text] [Related]
5. A safe and effective use of caplacizumab in pregnancy-related acquired thrombotic thrombocytopenic purpura.
Odetola O; Martin KA; Dreyer M; Rajan P; Zakarija A; Stein BL
Br J Haematol; 2023 Aug; 202(4):879-882. PubMed ID: 37226361
[TBL] [Abstract][Full Text] [Related]
6. Successful use of a second course of caplacizumab in relapsed thrombotic thrombocytopenic purpura.
Shaffer J; Grove A
Platelets; 2022 Jul; 33(5):790-791. PubMed ID: 34565299
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura.
Goshua G; Sinha P; Hendrickson JE; Tormey C; Bendapudi PK; Lee AI
Blood; 2021 Feb; 137(7):969-976. PubMed ID: 33280030
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic plasma exchange in patients with thrombotic thrombocytopenic purpura: a retrospective multicenter study.
Korkmaz S; Keklik M; Sivgin S; Yildirim R; Tombak A; Kaya ME; Acik DY; Esen R; Hacioglu SK; Sencan M; Kiki I; Tiftik EN; Kuku I; Okan V; Yilmaz M; Demir C; Sari I; Altuntas F; Unal A; Ilhan O
Transfus Apher Sci; 2013 Jun; 48(3):353-8. PubMed ID: 23602056
[TBL] [Abstract][Full Text] [Related]
9. A Rare Case of Severe Manifestation of COVID-19 Infection Presenting as Immune-Related Thrombotic Thrombocytopenic Purpura With Multiorgan Involvement Treated With Plasmapheresis, Steroids, Rituximab, and Caplacizumab.
Mandyam S; Fatmi SS; Banzon G; Kaur P; Katamreddy Y; Parghi D; Farooq A; Liaqat H; Basarakodu K
Cureus; 2022 Jul; 14(7):e26961. PubMed ID: 35989829
[TBL] [Abstract][Full Text] [Related]
10. Rituximab for acute plasma-refractory thrombotic thrombocytopenic purpura: A case report.
Chaurasiya PS; Khatri A; Gurung S; Karki S; Shahi S; Aryal L
Ann Med Surg (Lond); 2022 Oct; 82():104789. PubMed ID: 36268380
[TBL] [Abstract][Full Text] [Related]
11. Non-ST-Segment Elevation Myocardial Infarction As Initial Thrombotic Event of Thrombotic Thrombocytopenic Purpura: A Rare Challenging Case.
Mohamed KH; Shiza ST; Samreen I; Agboola AA; Mohamed AS; Kalluru PKR; Haseeb M; Munawar RZ; Nasir H
Cureus; 2023 Mar; 15(3):e36363. PubMed ID: 37082484
[TBL] [Abstract][Full Text] [Related]
12. Caplacizumab Use in a TTP Case Unresponsive to Conventional Therapy.
William J; McCellistrim C; Nuñez Y
Ir Med J; 2022 Sep; 115(8):656. PubMed ID: 36327969
[TBL] [Abstract][Full Text] [Related]
13. Caplacizumab: an anti-von Willebrand factor antibody for the treatment of thrombotic thrombocytopenic purpura.
Hollifield AL; Arnall JR; Moore DC
Am J Health Syst Pharm; 2020 Jul; 77(15):1201-1207. PubMed ID: 32588878
[TBL] [Abstract][Full Text] [Related]
14. Post Approval Experience with Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura at a Single Institution.
Logothetis CN; Patel A; Eatrides J; Jaglal M; Haider M; Visweshwar N; Laber DA
J Clin Med; 2021 Jul; 10(15):. PubMed ID: 34362201
[TBL] [Abstract][Full Text] [Related]
15. Case Report: Two Cases of Pediatric Thrombotic Thrombocytopenic Purpura Treated With Combined Therapy.
Tripiciano C; Zangari P; Montanari M; Leone G; Massella L; Garaboldi L; Massoud M; Lancellotti S; Strocchio L; Manno EC; Palma P; Corsetti T; Luciani M
Front Pediatr; 2021; 9():743206. PubMed ID: 34796152
[TBL] [Abstract][Full Text] [Related]
16. First diagnosis of thrombotic thrombocytopenic purpura after SARS-CoV-2 vaccine - case report.
Osmanodja B; Schreiber A; Schrezenmeier E; Seelow E
BMC Nephrol; 2021 Dec; 22(1):411. PubMed ID: 34895163
[TBL] [Abstract][Full Text] [Related]
17. An Interesting Case of Refractory Thrombotic Thrombocytopenic Purpura in the First Trimester of a Twin Pregnancy.
Jacob G; Dhaliwal A; Chaudhary V
Cureus; 2023 Oct; 15(10):e47153. PubMed ID: 38021667
[TBL] [Abstract][Full Text] [Related]
18. Delayed Thrombotic Complications in a Thrombotic Thrombocytopenic Purpura Patient Treated With Caplacizumab.
Cilla N; Dallemagne J; Vanhove M; Stordeur P; Motte S; De Wilde V
J Hematol; 2020 Sep; 9(3):84-88. PubMed ID: 32855757
[TBL] [Abstract][Full Text] [Related]
19. Clinical Efficacy and Safety Profile of Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.
Maqsood MH; Rubab K; Maqsood MZ
Cureus; 2019 Jul; 11(7):e5263. PubMed ID: 31576256
[TBL] [Abstract][Full Text] [Related]
20. Severe HELLP syndrome masquerading as thrombocytopenic thrombotic purpura: a case report.
Mousseaux C; Joly BS; Mohamadou I; Arrestier R; Hertig A; Rafat C
BMC Nephrol; 2020 May; 21(1):204. PubMed ID: 32471388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
